Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

被引：0
|
作者：
Andric, Z. [1 ]
Ceric, T. [2 ]
Stanetic, M. [3 ]
Rancic, M. [4 ]
Jakopovic, M. [5 ]
Aix, S. Ponce [6 ]
Ramlau, R. [7 ]
Smit, E. [8 ]
Ulanska, M. [9 ]
Caldwell, C. [10 ]
Ferrari, D. [10 ]
Annis, A. [11 ]
Vukovic, V. [10 ]
Zaric, B. [12 ]
机构：
[1] CHC Bezanijska Kosa, Med Oncol, Belgrade, Serbia
[2] Univ Clin Ctr Sarajevo, Med Oncol, Sarajevo, Bosnia & Herceg
[3] Univ Clin Ctr Lung Clin, Med Oncol, Banja Luka, Bosnia & Herceg
[4] Clin Pulm Dis Nis, Med Oncol, Nish, Serbia
[5] Clin Lung Dis Jordanovac, Med Oncol, Zagreb, Croatia
[6] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain
[7] Poznan Univ Med Sci, Med Oncol, Poznan, Poland
[8] Stichting Het Nederlands Kanker Inst, Med Oncol, Amsterdam, Netherlands
[9] Ctr Terapii Wspolczesnej, Med Oncol, Lodz, Poland
[10] Aileron Therapeut Inc, Clin Dev, Watertown, MA USA
[11] Aileron Therapeut Inc, Translat Res, Watertown, MA USA
[12] Inst Pulm Dis, Med Oncol, Novi Sad, Serbia
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96LBA
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [1] A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
    Andric, Z.
    Ceric, T.
    Rancic, M.
    Jakopovic, M.
    Aix, S. Ponce
    Ramlau, R.
    Ulanska, M.
    Caldwell, C.
    Ferrari, D.
    Annis, A.
    Vukovic, V.
    Zaric, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1166 - S1166
  • [2] ALRN-6924 IS A DUAL MDMX/MDM2 INHIBITOR AND CAN PROTECT THE BONE MARROW OF CANCER PATIENTS TREATED WITH CHEMOTHERAPY
    Vukovic, Vojislav
    Annis, Allen
    Ferrari, Dora
    Aivado, Manuel
    [J]. EXPERIMENTAL HEMATOLOGY, 2021, 100 : S61 - S61
  • [3] The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
    Carvajal, Luis A.
    Sutton, David
    Mounir, Mariam
    McClanaghan, Joseph
    Guerlavais, Vincent
    Aivado, Manuel
    Vukovic, Vojislav
    Annis, Allen
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [4] The investigational chemoprotection drug ALRN-6924, a dual inhibitor of MDMX and MDM2, shows potential for radioprotection
    Annis, Allen
    Sutton, David
    Aivado, Manuel
    Vukovic, Vojislav
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [5] Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2
    Shustov, Andrei R.
    Mehta, Amitkumar
    Sokol, Lubomir
    Carvajal, Luis A.
    Guerlavais, Vincent
    Samant, Manoj
    Narasimhan, Narayana
    Sutton, David
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Korn, Ronald
    [J]. BLOOD, 2018, 132
  • [6] A phase I pharmacology study of the dual MDMX/MDM2 inhibitor, ALRN 6924, in healthy volunteers
    Voors-Pette, C.
    Aalders, W.
    Brill, M.
    Ferrari, D.
    Annis, A.
    Steidl, U.
    Aivado, M.
    Vukovic, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1222 - S1223
  • [7] ALRN-6924, a dual inhibitor of MDMX and MDM2, protects human scalp hair follicles and their epithelial stem cells from paclitaxel-induced toxicity
    Gherardini, J.
    Annis, A. D.
    Cheret, J.
    Aivado, M.
    Paus, R.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B33 - B33
  • [8] A Phase I multicenter trial of the dual MDM2/MDMX inhibitor ALRN-6924 in children and young adults with relapsed/refractory pediatric cancers
    Shulman, David S.
    Vo, Kieuhoa T.
    Fox, Elizabeth
    Muscal, Jodi A.
    Walensky, Loren D.
    Pikman, Yana
    Stegmaier, Kimberly
    Church, Alanna
    Crompton, Brian D.
    Place, Andrew E.
    Chi, Susan N.
    O'Neill, Allison F.
    Kamihara, Junne
    Ezrre, Suzanne
    Carlowicz, Cecilia
    Pinchasik, Dawn
    Al-Sayegh, Hasan
    Ma, Clement
    London, Wendy B.
    DuBois, Steven G.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies
    Annis, A.
    Ren, J. G.
    Carvajal, L. A.
    Santiago, S.
    Narasimhan, N.
    Sutton, D.
    Pairawan, S. S.
    Guerlavais, V.
    Meric-Bernstam, F.
    Aivado, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E143 - E144
  • [10] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey, I
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
12345